TFX Share Price | Teleflex, Inc. Stock Analysis & Recommendation

Q: What does Teleflex, Inc. do?

Overview:Teleflex, Inc. is a provider of medical technology products in the Pharmaceuticals & Biotechnology industry, operating in the mid-cap market segment.Financial Snapshot:Most recent Net Sales: 701 Million (Quarterly Results - Mar 2025)Most recent Net Profit: 95 Million (Quarterly Results - Mar 2025)Market-cap: USD 5,319.41 Million (Mid Cap)Key Metrics:P/E: 13.00Dividend Yield: 1.20%Debt Equity: 0.40Return on Equity: 10.18%Price to Book: 1.30Contact Details:Address: 550 E Swedesford Rd Ste 400, WAYNE PA: 19087-1601Tel: ['1 610 2256800', '1 610 9482836']Fax: 1 610 9485101Website: https://www.teleflex.com/

Q: Is Teleflex, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Teleflex, Inc. has moved from attractive to very expensive, indicating a shift towards overvaluation. The company appears overvalued based on its current metrics, with a P/E ratio of 13, an EV to EBITDA of 8.74, and a PEG ratio of 0.39. In comparison, peers such as Hologic, Inc. have a P/E of 21.83, while The Cooper Cos., Inc. shows a significantly higher P/E of 34.28, further emphasizing Teleflex's relative overvaluation.Recent performance shows that Teleflex has underperformed compared to the S&P 500, with a year-to-date return of -28.01% against the index's 13.30%. This trend continues over longer periods, with a 5-year return of -64.93% compared to the S&P 500's 91.29%, reinforcing the notion that Teleflex is currently overvalued in the market.

Q: Is Teleflex, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Teleflex, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Moving averages are bearish on the daily timeframe. The KST is bullish weekly but bearish monthly, and Dow Theory suggests a mildly bearish outlook on the weekly chart with no trend monthly. In terms of performance, Teleflex has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -30.10% versus the S&P 500's 16.30%, and a one-year return of -41.10% compared to 19.89% for the index. Overall, the current technical stance is mildly bearish, driven by the bearish moving averages and mixed signals from MACD and KST.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

826.08 k

Shareholding (Dec 2025)

FII

14.34%

Held by 276 FIIs

DII

2.66%

Held by 90 DIIs

Promoter

0.36%

How big is Teleflex, Inc.?

22-Jun-2025

As of Jun 18, Teleflex, Inc. has a market capitalization of $5.32 billion, with net sales of $3.01 billion and a net profit of $149.53 million for the latest four quarters. The balance sheet shows shareholder's funds of $4.28 billion and total assets of $7.10 billion.

View full answer

What does Teleflex, Inc. do?

22-Jun-2025

Teleflex, Inc. is a mid-cap provider of medical technology products in the Pharmaceuticals & Biotechnology industry, with recent net sales of $701 million and a market cap of approximately $5.32 billion. Key financial metrics include a P/E ratio of 13.00 and a dividend yield of 1.20%.

View full answer

Who are in the management team of Teleflex, Inc.?

22-Jun-2025

As of March 2022, the management team of Teleflex, Inc. includes Liam Kelly as Chairman, President, and CEO, with George Babich as Lead Independent Director and several Independent Directors: Candace Duncan, Gretchen Haggerty, John Heinmiller, and Stephen Klasko.

View full answer

Is Teleflex, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Teleflex, Inc. is considered very expensive and overvalued, with a P/E ratio of 13 and significant underperformance compared to the S&P 500, showing a year-to-date return of -28.01% and a 5-year return of -64.93%.

View full answer

Is Teleflex, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Teleflex, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly, having a year-to-date return of -30.10% compared to the index's 16.30%.

View full answer

Compare Teleflex, Inc. with Similar Stocks

Insulet Corp.EXACT Sciences Corp.Revvity, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 3.78% and Operating profit at 3.08% over the last 5 years

INTEREST(Q) At USD 24.95 MM has Grown at 17.73%
DIVIDEND PAYOUT RATIO(Y) Lowest at 12.3%
DEBT-EQUITY RATIO (HY) Highest at 40.7 %

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4,945 Million (Small Cap)

P/E

10.00

Industry P/E

Dividend Yield

1.29%

Debt Equity

0.60

Return on Equity

12.46%

Price to Book

1.29

Revenue and Profits:

Net Sales:

569 Million

(Quarterly Results - Dec 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-11.57%

6 Months

-7.54%

1 Year

-22.31%

2 Years

-50.75%

3 Years

-56.54%

4 Years

-68.13%

5 Years

-73.63%

Teleflex, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

4.94%

EBIT Growth (5y)

2.39%

EBIT to Interest (avg)

5.78

Debt to EBITDA (avg)

2.12

Net Debt to Equity (avg)

0.40

Sales to Capital Employed (avg)

0.49

Tax Ratio

28.88%

Dividend Payout Ratio

91.92%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

9.41%

ROE (avg)

9.86%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.29

EV to EBIT

12.77

EV to EBITDA

8.52

EV to Capital Employed

1.18

EV to Sales

2.27

PEG Ratio

0.12

Dividend Yield

1.29%

ROCE (Latest)

9.26%

ROE (Latest)

12.46%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 135 Schemes (81.92%)

Foreign Institutions

Held by 276 Foreign Institutions (14.34%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -28.46% vs 2.78% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 97.37% vs -538.14% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "569.00",
          "val2": "795.40",
          "chgp": "-28.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "38.20",
          "val2": "216.70",
          "chgp": "-82.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "35.00",
          "val2": "22.90",
          "chgp": "52.84%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-23.40",
          "val2": "-255.30",
          "chgp": "90.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.60",
          "val2": "-136.70",
          "chgp": "97.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "67.20%",
          "val2": "182.20%",
          "chgp": "-11.50%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 17.25% vs -42.86% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 2.27% vs -84.00% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,992.70",
          "val2": "1,699.50",
          "chgp": "17.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "455.10",
          "val2": "413.80",
          "chgp": "9.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "120.30",
          "val2": "102.50",
          "chgp": "17.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-156.90",
          "val2": "-17.50",
          "chgp": "-796.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "58.50",
          "val2": "57.20",
          "chgp": "2.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "139.20%",
          "val2": "148.40%",
          "chgp": "-0.92%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

569.00

795.40

-28.46%

Operating Profit (PBDIT) excl Other Income

38.20

216.70

-82.37%

Interest

35.00

22.90

52.84%

Exceptional Items

-23.40

-255.30

90.83%

Consolidate Net Profit

-3.60

-136.70

97.37%

Operating Profit Margin (Excl OI)

67.20%

182.20%

-11.50%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is -28.46% vs 2.78% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 97.37% vs -538.14% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1,992.70

1,699.50

17.25%

Operating Profit (PBDIT) excl Other Income

455.10

413.80

9.98%

Interest

120.30

102.50

17.37%

Exceptional Items

-156.90

-17.50

-796.57%

Consolidate Net Profit

58.50

57.20

2.27%

Operating Profit Margin (Excl OI)

139.20%

148.40%

-0.92%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 17.25% vs -42.86% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 2.27% vs -84.00% in Dec 2024

All Annual Results

Company CV

About Teleflex, Inc.

Teleflex, Inc.

Pharmaceuticals & Biotechnology

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company's products include oxygen therapy products, aerosol therapy products, spirometry products, and ventilation management products, which are offered under Hudson RCI brand. As of December 31, 2016, it manufactured its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. Its all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.

Company Coordinates

Company Details

550 E Swedesford Rd Ste 400 , WAYNE PA : 19087-1601

Tel: 1 610 22568001 610 9482836

https://www.teleflex.com/

Registrar Details